CN114533737B - 治疗眼部病状的方法 - Google Patents
治疗眼部病状的方法 Download PDFInfo
- Publication number
- CN114533737B CN114533737B CN202210034408.5A CN202210034408A CN114533737B CN 114533737 B CN114533737 B CN 114533737B CN 202210034408 A CN202210034408 A CN 202210034408A CN 114533737 B CN114533737 B CN 114533737B
- Authority
- CN
- China
- Prior art keywords
- formula
- compound
- iiib
- iiia
- nasal cavity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000000034 method Methods 0.000 title abstract description 655
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 134
- 230000001965 increasing effect Effects 0.000 claims description 322
- FNEHSHNEXMPCLJ-VWCDRPFISA-N 5-[(e)-2-[(3r)-pyrrolidin-3-yl]ethenyl]pyrimidine Chemical compound C1NCC[C@@H]1\C=C\C1=CN=CN=C1 FNEHSHNEXMPCLJ-VWCDRPFISA-N 0.000 claims description 253
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 248
- 150000003839 salts Chemical class 0.000 claims description 221
- 208000003556 Dry Eye Syndromes Diseases 0.000 claims description 218
- 206010013774 Dry eye Diseases 0.000 claims description 206
- 230000004489 tear production Effects 0.000 claims description 198
- 108010019783 tear proteins Proteins 0.000 claims description 153
- 206010052143 Ocular discomfort Diseases 0.000 claims description 113
- 239000007788 liquid Substances 0.000 claims description 55
- -1 salt dihydrate Chemical class 0.000 claims description 54
- 238000001356 surgical procedure Methods 0.000 claims description 38
- 239000006199 nebulizer Substances 0.000 claims description 33
- 238000011282 treatment Methods 0.000 claims description 31
- HVGZXVVUVQKTSC-OUCPDFHMSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid 5-[(E)-2-[(3R)-pyrrolidin-3-yl]ethenyl]pyrimidine Chemical group C1NCC[C@@H]1\C=C\C1=CN=CN=C1.OC(=O)CC(O)(C(O)=O)CC(O)=O HVGZXVVUVQKTSC-OUCPDFHMSA-N 0.000 claims description 25
- 239000003814 drug Substances 0.000 claims description 21
- 239000006200 vaporizer Substances 0.000 claims description 17
- 230000008439 repair process Effects 0.000 claims description 12
- 208000002177 Cataract Diseases 0.000 claims description 11
- 239000012458 free base Substances 0.000 claims description 11
- 238000001959 radiotherapy Methods 0.000 claims description 11
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims description 8
- 208000024891 symptom Diseases 0.000 claims description 8
- 229960002715 nicotine Drugs 0.000 claims description 7
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims description 7
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical group [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 6
- 208000010412 Glaucoma Diseases 0.000 claims description 6
- 208000002367 Retinal Perforations Diseases 0.000 claims description 6
- 206010038848 Retinal detachment Diseases 0.000 claims description 6
- 208000029233 macular holes Diseases 0.000 claims description 6
- 210000001328 optic nerve Anatomy 0.000 claims description 6
- 230000000649 photocoagulation Effects 0.000 claims description 6
- 230000004264 retinal detachment Effects 0.000 claims description 6
- 230000002207 retinal effect Effects 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 5
- 208000002193 Pain Diseases 0.000 claims description 4
- 102100026607 ALS2 C-terminal-like protein Human genes 0.000 claims description 3
- 101800000414 Corticotropin Proteins 0.000 claims description 3
- 101000717960 Homo sapiens ALS2 C-terminal-like protein Proteins 0.000 claims description 3
- 101000804964 Homo sapiens DNA polymerase subunit gamma-1 Proteins 0.000 claims description 3
- 101000595929 Homo sapiens POLG alternative reading frame Proteins 0.000 claims description 3
- 101001067189 Homo sapiens Plexin-A1 Proteins 0.000 claims description 3
- 101000731732 Homo sapiens Rho guanine nucleotide exchange factor 19 Proteins 0.000 claims description 3
- 101000650148 Homo sapiens WD repeat domain phosphoinositide-interacting protein 1 Proteins 0.000 claims description 3
- 101000915475 Homo sapiens Zinc finger MIZ domain-containing protein 2 Proteins 0.000 claims description 3
- 101710024993 KIAA1109 Proteins 0.000 claims description 3
- 108010063045 Lactoferrin Proteins 0.000 claims description 3
- 108010022337 Leucine Enkephalin Proteins 0.000 claims description 3
- 206010028980 Neoplasm Diseases 0.000 claims description 3
- 102100035196 POLG alternative reading frame Human genes 0.000 claims description 3
- 102100034382 Plexin-A1 Human genes 0.000 claims description 3
- 102000003946 Prolactin Human genes 0.000 claims description 3
- 108010057464 Prolactin Proteins 0.000 claims description 3
- 102100032433 Rho guanine nucleotide exchange factor 19 Human genes 0.000 claims description 3
- 102100025378 Transmembrane protein KIAA1109 Human genes 0.000 claims description 3
- 102100027543 WD repeat domain phosphoinositide-interacting protein 1 Human genes 0.000 claims description 3
- 102100028536 Zinc finger MIZ domain-containing protein 2 Human genes 0.000 claims description 3
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 claims description 3
- 229960000258 corticotropin Drugs 0.000 claims description 3
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 claims description 3
- 229940078795 lactoferrin Drugs 0.000 claims description 3
- 235000021242 lactoferrin Nutrition 0.000 claims description 3
- URLZCHNOLZSCCA-UHFFFAOYSA-N leu-enkephalin Chemical compound C=1C=C(O)C=CC=1CC(N)C(=O)NCC(=O)NCC(=O)NC(C(=O)NC(CC(C)C)C(O)=O)CC1=CC=CC=C1 URLZCHNOLZSCCA-UHFFFAOYSA-N 0.000 claims description 3
- 229940097325 prolactin Drugs 0.000 claims description 3
- 102100034719 Extracellular glycoprotein lacritin Human genes 0.000 claims description 2
- 101001090521 Homo sapiens Extracellular glycoprotein lacritin Proteins 0.000 claims description 2
- 206010034960 Photophobia Diseases 0.000 claims description 2
- 102100027467 Pro-opiomelanocortin Human genes 0.000 claims description 2
- 208000003251 Pruritus Diseases 0.000 claims description 2
- 230000007803 itching Effects 0.000 claims description 2
- 230000036407 pain Effects 0.000 claims description 2
- 230000035807 sensation Effects 0.000 claims description 2
- 239000007922 nasal spray Substances 0.000 claims 2
- 229940097496 nasal spray Drugs 0.000 claims 2
- 102000009024 Epidermal Growth Factor Human genes 0.000 claims 1
- 101800003838 Epidermal growth factor Proteins 0.000 claims 1
- 241000282326 Felis catus Species 0.000 claims 1
- 102100032241 Lactotransferrin Human genes 0.000 claims 1
- 241001465754 Metazoa Species 0.000 claims 1
- 241000283973 Oryctolagus cuniculus Species 0.000 claims 1
- 239000013583 drug formulation Substances 0.000 claims 1
- 229940116977 epidermal growth factor Drugs 0.000 claims 1
- 244000144972 livestock Species 0.000 claims 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 description 1668
- 210000003928 nasal cavity Anatomy 0.000 description 930
- 108050006807 Nicotinic acetylcholine receptors Proteins 0.000 description 245
- 102000019315 Nicotinic acetylcholine receptors Human genes 0.000 description 245
- 210000001508 eye Anatomy 0.000 description 221
- 230000002093 peripheral effect Effects 0.000 description 182
- 230000036541 health Effects 0.000 description 153
- 230000007613 environmental effect Effects 0.000 description 141
- 125000000217 alkyl group Chemical group 0.000 description 112
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 84
- 102000003923 Protein Kinase C Human genes 0.000 description 83
- 108090000315 Protein Kinase C Proteins 0.000 description 83
- 125000001072 heteroaryl group Chemical group 0.000 description 76
- 230000000694 effects Effects 0.000 description 63
- 239000001257 hydrogen Substances 0.000 description 60
- 229910052739 hydrogen Inorganic materials 0.000 description 60
- 239000000126 substance Substances 0.000 description 57
- 238000011200 topical administration Methods 0.000 description 57
- 125000003118 aryl group Chemical group 0.000 description 56
- 102000001253 Protein Kinase Human genes 0.000 description 55
- 108060006633 protein kinase Proteins 0.000 description 55
- 230000008499 blood brain barrier function Effects 0.000 description 49
- 210000001218 blood-brain barrier Anatomy 0.000 description 49
- 230000000699 topical effect Effects 0.000 description 49
- 230000002354 daily effect Effects 0.000 description 46
- 238000000586 desensitisation Methods 0.000 description 46
- 150000002431 hydrogen Chemical class 0.000 description 44
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 description 40
- 238000011084 recovery Methods 0.000 description 33
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 32
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 description 32
- 230000002265 prevention Effects 0.000 description 32
- 230000009885 systemic effect Effects 0.000 description 30
- 102000008130 Cyclic AMP-Dependent Protein Kinases Human genes 0.000 description 28
- 108010049894 Cyclic AMP-Dependent Protein Kinases Proteins 0.000 description 28
- 229940122739 Calcineurin inhibitor Drugs 0.000 description 26
- 101710192106 Calcineurin-binding protein cabin-1 Proteins 0.000 description 26
- 102100024123 Calcineurin-binding protein cabin-1 Human genes 0.000 description 26
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 24
- 229940046731 calcineurin inhibitors Drugs 0.000 description 20
- 229910052736 halogen Inorganic materials 0.000 description 20
- 150000002367 halogens Chemical class 0.000 description 20
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 19
- 108010036949 Cyclosporine Proteins 0.000 description 19
- 229960001265 ciclosporin Drugs 0.000 description 19
- 229930182912 cyclosporin Natural products 0.000 description 19
- 230000000506 psychotropic effect Effects 0.000 description 19
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 18
- 239000000499 gel Substances 0.000 description 18
- 239000002674 ointment Substances 0.000 description 18
- KASDHRXLYQOAKZ-ZPSXYTITSA-N pimecrolimus Chemical compound C/C([C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@@H](OC)C[C@@H](C)C/C(C)=C/[C@H](C(C[C@H](O)[C@H]1C)=O)CC)=C\[C@@H]1CC[C@@H](Cl)[C@H](OC)C1 KASDHRXLYQOAKZ-ZPSXYTITSA-N 0.000 description 18
- 229960005330 pimecrolimus Drugs 0.000 description 18
- 229960001967 tacrolimus Drugs 0.000 description 18
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 18
- 244000062730 Melissa officinalis Species 0.000 description 17
- 235000010654 Melissa officinalis Nutrition 0.000 description 17
- 239000000443 aerosol Substances 0.000 description 17
- 239000006071 cream Substances 0.000 description 17
- 239000000865 liniment Substances 0.000 description 17
- 239000006210 lotion Substances 0.000 description 17
- 239000006072 paste Substances 0.000 description 17
- 239000000843 powder Substances 0.000 description 17
- 239000000725 suspension Substances 0.000 description 17
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 16
- 229910052757 nitrogen Inorganic materials 0.000 description 16
- 229940098458 powder spray Drugs 0.000 description 16
- 230000001154 acute effect Effects 0.000 description 15
- 125000000753 cycloalkyl group Chemical group 0.000 description 12
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 12
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 12
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 12
- 208000014829 head and neck neoplasm Diseases 0.000 description 10
- 229940125904 compound 1 Drugs 0.000 description 8
- 125000000714 pyrimidinyl group Chemical group 0.000 description 8
- 230000011514 reflex Effects 0.000 description 8
- 125000001424 substituent group Chemical group 0.000 description 8
- 150000004683 dihydrates Chemical class 0.000 description 7
- 150000004682 monohydrates Chemical class 0.000 description 7
- 210000005036 nerve Anatomy 0.000 description 7
- 230000001737 promoting effect Effects 0.000 description 7
- 210000003901 trigeminal nerve Anatomy 0.000 description 7
- 230000000144 pharmacologic effect Effects 0.000 description 6
- 238000000605 extraction Methods 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 210000003128 head Anatomy 0.000 description 5
- 230000008821 health effect Effects 0.000 description 5
- 230000007774 longterm Effects 0.000 description 5
- 208000026037 malignant tumor of neck Diseases 0.000 description 5
- 102000005962 receptors Human genes 0.000 description 5
- 108020003175 receptors Proteins 0.000 description 5
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 description 4
- 125000001766 1,2,4-oxadiazol-3-yl group Chemical group [H]C1=NC(*)=NO1 0.000 description 4
- 125000004505 1,2,4-oxadiazol-5-yl group Chemical group O1N=CN=C1* 0.000 description 4
- 125000004515 1,2,4-thiadiazol-3-yl group Chemical group S1N=C(N=C1)* 0.000 description 4
- 125000004516 1,2,4-thiadiazol-5-yl group Chemical group S1N=CN=C1* 0.000 description 4
- 125000004509 1,3,4-oxadiazol-2-yl group Chemical group O1C(=NN=C1)* 0.000 description 4
- 125000004521 1,3,4-thiadiazol-2-yl group Chemical group S1C(=NN=C1)* 0.000 description 4
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 description 4
- 125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 description 4
- KDDQRKBRJSGMQE-UHFFFAOYSA-N 4-thiazolyl Chemical group [C]1=CSC=N1 KDDQRKBRJSGMQE-UHFFFAOYSA-N 0.000 description 4
- CWDWFSXUQODZGW-UHFFFAOYSA-N 5-thiazolyl Chemical group [C]1=CN=CS1 CWDWFSXUQODZGW-UHFFFAOYSA-N 0.000 description 4
- GTUIQNHJSXQMKW-OCAPTIKFSA-N [(3aS,6aR)-2,3,3a,4,6,6a-hexahydro-1H-pyrrolo[3,4-c]pyrrol-5-yl]-(5-chlorofuran-2-yl)methanone Chemical compound Clc1ccc(o1)C(=O)N1C[C@@H]2CNC[C@@H]2C1 GTUIQNHJSXQMKW-OCAPTIKFSA-N 0.000 description 4
- 239000000556 agonist Substances 0.000 description 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 4
- 229910052794 bromium Inorganic materials 0.000 description 4
- 239000000460 chlorine Substances 0.000 description 4
- 229910052801 chlorine Inorganic materials 0.000 description 4
- 229910052731 fluorine Inorganic materials 0.000 description 4
- 229910052740 iodine Inorganic materials 0.000 description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 4
- 125000004076 pyridyl group Chemical group 0.000 description 4
- 125000005493 quinolyl group Chemical group 0.000 description 4
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 3
- 229940122578 Acetylcholine receptor agonist Drugs 0.000 description 3
- 206010057412 Iris neoplasm Diseases 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 102000010445 Lactoferrin Human genes 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 230000008472 epithelial growth Effects 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 210000001428 peripheral nervous system Anatomy 0.000 description 2
- 230000001839 systemic circulation Effects 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 102000009660 Cholinergic Receptors Human genes 0.000 description 1
- 108010009685 Cholinergic Receptors Proteins 0.000 description 1
- 206010010744 Conjunctivitis allergic Diseases 0.000 description 1
- 206010013954 Dysphoria Diseases 0.000 description 1
- 208000029728 Eyelid disease Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000004310 Ion Channels Human genes 0.000 description 1
- 108090000862 Ion Channels Proteins 0.000 description 1
- 102000004086 Ligand-Gated Ion Channels Human genes 0.000 description 1
- 108090000543 Ligand-Gated Ion Channels Proteins 0.000 description 1
- 208000010415 Low Vision Diseases 0.000 description 1
- 206010065062 Meibomian gland dysfunction Diseases 0.000 description 1
- 206010057852 Nicotine dependence Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 108010026552 Proteome Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000025569 Tobacco Use disease Diseases 0.000 description 1
- 206010047571 Visual impairment Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 208000002205 allergic conjunctivitis Diseases 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000000607 artificial tear Substances 0.000 description 1
- 208000024998 atopic conjunctivitis Diseases 0.000 description 1
- 208000010217 blepharitis Diseases 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 230000006727 cell loss Effects 0.000 description 1
- 239000003576 central nervous system agent Substances 0.000 description 1
- 229940125693 central nervous system agent Drugs 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000000064 cholinergic agonist Substances 0.000 description 1
- 201000007717 corneal ulcer Diseases 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 210000000744 eyelid Anatomy 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 230000006589 gland dysfunction Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000004941 influx Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 210000004561 lacrimal apparatus Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000003767 neural control Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229940012843 omega-3 fatty acid Drugs 0.000 description 1
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910001414 potassium ion Inorganic materials 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 210000001044 sensory neuron Anatomy 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 229910001415 sodium ion Inorganic materials 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 231100000607 toxicokinetics Toxicity 0.000 description 1
- 208000029257 vision disease Diseases 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Ophthalmology & Optometry (AREA)
- Otolaryngology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210034408.5A CN114533737B (zh) | 2016-04-07 | 2017-04-06 | 治疗眼部病状的方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662319648P | 2016-04-07 | 2016-04-07 | |
| US62/319,648 | 2016-04-07 | ||
| CN202210034408.5A CN114533737B (zh) | 2016-04-07 | 2017-04-06 | 治疗眼部病状的方法 |
| PCT/US2017/026385 WO2017177024A1 (en) | 2016-04-07 | 2017-04-06 | Methods of treating ocular conditions |
| CN201780034734.3A CN109310692B (zh) | 2016-04-07 | 2017-04-06 | 治疗眼部病状的方法 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201780034734.3A Division CN109310692B (zh) | 2016-04-07 | 2017-04-06 | 治疗眼部病状的方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN114533737A CN114533737A (zh) | 2022-05-27 |
| CN114533737B true CN114533737B (zh) | 2024-05-31 |
Family
ID=58549326
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210034408.5A Active CN114533737B (zh) | 2016-04-07 | 2017-04-06 | 治疗眼部病状的方法 |
| CN201780034734.3A Active CN109310692B (zh) | 2016-04-07 | 2017-04-06 | 治疗眼部病状的方法 |
| CN202210040168.XA Pending CN114432313A (zh) | 2016-04-07 | 2017-04-06 | 治疗眼部病状的方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201780034734.3A Active CN109310692B (zh) | 2016-04-07 | 2017-04-06 | 治疗眼部病状的方法 |
| CN202210040168.XA Pending CN114432313A (zh) | 2016-04-07 | 2017-04-06 | 治疗眼部病状的方法 |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US10709707B2 (https=) |
| EP (2) | EP3439661B1 (https=) |
| JP (3) | JP7090551B2 (https=) |
| KR (2) | KR102485299B1 (https=) |
| CN (3) | CN114533737B (https=) |
| AU (1) | AU2017248276B2 (https=) |
| DK (1) | DK3439661T3 (https=) |
| EA (1) | EA201892265A1 (https=) |
| ES (1) | ES2893126T3 (https=) |
| IL (3) | IL299204A (https=) |
| MX (2) | MX385698B (https=) |
| MY (1) | MY199237A (https=) |
| NZ (1) | NZ746468A (https=) |
| PH (1) | PH12018502154A1 (https=) |
| PT (1) | PT3439661T (https=) |
| SG (1) | SG11201808650QA (https=) |
| TW (2) | TWI876258B (https=) |
| WO (1) | WO2017177024A1 (https=) |
| ZA (1) | ZA201807438B (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9145396B2 (en) | 2008-12-01 | 2015-09-29 | Targacept, Inc. | Synthesis and novel salt forms of (R)-5-((E)-2-pyrrolidin-3ylvinyl)pyrimidine |
| EP3848028B9 (en) | 2014-10-20 | 2024-10-16 | Oyster Point Pharma, Inc. | Methods of treating ocular conditions |
| MX385698B (es) | 2016-04-07 | 2025-03-18 | Oyster Point Pharma Inc | Uso de un compuesto que comprende un grupo pirrolidinilo y pirimidinilo para tratar enfermedades oculares |
| EP3820443A1 (en) | 2018-07-10 | 2021-05-19 | Oyster Point Pharma, Inc. | Combinations of positive allosteric modulators and nicotinic acetylcholine receptor agonists for treating ocular conditions |
| WO2020014217A1 (en) | 2018-07-10 | 2020-01-16 | Oyster Point Pharma, Inc. | Methods of treating ocular conditions |
| ES3039903T3 (en) * | 2020-04-28 | 2025-10-27 | Oyster Point Pharma Inc | Local administration of nicotinic acetylcholine receptor agonists for the inhibition of coronavirus infections |
| KR20240021783A (ko) * | 2021-05-07 | 2024-02-19 | 오이스터 포인트 파마 인코포레이티드 | 벡터 및 니코틴 작용제 병용 요법 |
| WO2026080563A1 (en) | 2024-10-09 | 2026-04-16 | Oyster Point Pharma, Inc. | Simpinicline oral formations and use thereof |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6277855B1 (en) * | 2000-04-21 | 2001-08-21 | Inspire Pharmaceuticals, Inc. | Method of treating dry eye disease with nicotinic acetylcholine receptor agonists |
| WO2004039366A1 (en) * | 2002-11-01 | 2004-05-13 | Pharmacia & Upjohn Company Llc | Nicotinic acetylcholine agonists in the treatment of glaucoma and retinal neuropathy |
| WO2010065443A1 (en) * | 2008-12-01 | 2010-06-10 | Targacept, Inc. | Synthesis and novel salt forms of (r)-5-((e)-2-(pyrrolidin-3-ylvinyl)pyrimidine |
| CN102216289A (zh) * | 2008-10-14 | 2011-10-12 | 塞扣吉尼克斯公司 | 烟碱乙酰胆碱受体配体及其用途 |
| CN109310692B (zh) * | 2016-04-07 | 2022-01-25 | 奥伊斯特普安生物制药公司 | 治疗眼部病状的方法 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030008892A1 (en) | 2001-07-09 | 2003-01-09 | Pfizer Inc. | Pharmaceutical composition and method of modulating cholinergic function in a mammal |
| EP1461040B1 (en) | 2001-11-29 | 2006-03-15 | Pfizer Products Inc. | Succinic acid salts of 5,8,14-triazatetracyclo[10.3.1.0 2,11 .0 4,9 ]-hexadeca-2(11),3,5,7,9,-pentaene and pharmaceutical compositions thereof |
| US7098331B2 (en) | 2003-03-05 | 2006-08-29 | Targacept, Inc. | Arylvinylazacycloalkane compounds and methods of preparation and use thereof |
| US20060270592A1 (en) | 2004-03-19 | 2006-11-30 | Ophthalmic Research Associates, Inc. | Use of neurotransmitters and neuropeptides for the treatment of dry eye diseases and related conditions |
| MX2007004495A (es) | 2004-10-15 | 2007-05-10 | Pfizer Prod Inc | Composiciones y procedimientos para la administracion intranasal, bucal, sublingual y pulmonar de vareniclina. |
| WO2006100075A2 (en) | 2005-03-22 | 2006-09-28 | Niconovum Ab | Use of an artificial sweetener to enhance absorption of nicotine |
| US20110086086A1 (en) | 2005-07-26 | 2011-04-14 | Pfizer Inc | Transdermal system for varenicline |
| TWI454262B (zh) | 2006-11-02 | 2014-10-01 | Targacept Inc | 菸鹼乙醯膽鹼受體亞型選擇性之二氮雜雙環烷類醯胺 |
| HRP20110702T1 (hr) | 2007-02-02 | 2011-10-31 | Pfizer Products Inc. | Triciklički spojevi i njihova uporaba kao modulatora glukokortikoidnih receptora |
| WO2008157365A2 (en) * | 2007-06-15 | 2008-12-24 | Targacept, Inc. | Vinylazacycloalkanes for treating neuropathic pain |
| US20090093446A1 (en) | 2007-10-05 | 2009-04-09 | Winston Laboratories, Inc. | Method for alleviating keratoconjunctivitis sicca |
| CL2008003507A1 (es) | 2007-11-26 | 2009-11-27 | Neuroderm Ltd | Composicion farmaceutica que comprende nicotina y un inhibidor de la desensibilizacion del receptor de acetilcolina nicotinico (nachr) opipramol; kit farmaceutico; dispositivo medico; y uso para tratar una enfermedad o trastorno del sistema nervioso central o periferico. |
| JP2011513421A (ja) | 2008-03-05 | 2011-04-28 | ターガセプト，インコーポレイテッド | サブタイプ選択的なジアザビシクロアルカンのアミド |
| WO2010028011A1 (en) | 2008-09-05 | 2010-03-11 | Targacept, Inc. | Amides of diazabicyclononanes and uses thereof |
| WO2010028033A1 (en) | 2008-09-05 | 2010-03-11 | Targacept, Inc. | Amides of diazabicyclooctanes and uses thereof |
| TW201024283A (en) | 2008-12-01 | 2010-07-01 | Targacept Inc | Synthesis and novel salt forms of (R)-3-((E)-2-(pyrrolidin-3-yl)vinyl)-5-(tetrahydropyran-4-yloxy)pyridine |
| US9145396B2 (en) | 2008-12-01 | 2015-09-29 | Targacept, Inc. | Synthesis and novel salt forms of (R)-5-((E)-2-pyrrolidin-3ylvinyl)pyrimidine |
| BRPI1014247A2 (pt) * | 2009-06-17 | 2016-04-12 | Targacept Inc | reversão da discinesia induzida pela l-dopa por ligantes de receptores nocotínicos neuronais. |
| US20110274628A1 (en) | 2010-05-07 | 2011-11-10 | Borschke August J | Nicotine-containing pharmaceutical compositions |
| US8821457B2 (en) | 2010-09-08 | 2014-09-02 | Johnson & Johnson Vision Care, Inc. | Punctal plug containing drug formulation |
| ES2776996T3 (es) | 2011-10-20 | 2020-08-03 | Novartis Ag | Biomarcadores predictivos de la sensibilidad al tratamiento por el activador del receptor de la acetilcolina nicotínico alfa 7 |
| EP2786142A4 (en) | 2011-11-30 | 2015-07-22 | Diagnostear Ltd | DIAGNOSIS OF THE DRY EYE |
| EP3848028B9 (en) | 2014-10-20 | 2024-10-16 | Oyster Point Pharma, Inc. | Methods of treating ocular conditions |
-
2017
- 2017-04-06 MX MX2018012230A patent/MX385698B/es unknown
- 2017-04-06 CN CN202210034408.5A patent/CN114533737B/zh active Active
- 2017-04-06 TW TW112102845A patent/TWI876258B/zh active
- 2017-04-06 EP EP17718304.3A patent/EP3439661B1/en active Active
- 2017-04-06 JP JP2018553080A patent/JP7090551B2/ja active Active
- 2017-04-06 NZ NZ746468A patent/NZ746468A/en unknown
- 2017-04-06 TW TW106111559A patent/TWI790997B/zh active
- 2017-04-06 CN CN201780034734.3A patent/CN109310692B/zh active Active
- 2017-04-06 DK DK17718304.3T patent/DK3439661T3/da active
- 2017-04-06 SG SG11201808650QA patent/SG11201808650QA/en unknown
- 2017-04-06 EA EA201892265A patent/EA201892265A1/ru unknown
- 2017-04-06 AU AU2017248276A patent/AU2017248276B2/en active Active
- 2017-04-06 KR KR1020187032218A patent/KR102485299B1/ko active Active
- 2017-04-06 CN CN202210040168.XA patent/CN114432313A/zh active Pending
- 2017-04-06 WO PCT/US2017/026385 patent/WO2017177024A1/en not_active Ceased
- 2017-04-06 MY MYPI2018001700A patent/MY199237A/en unknown
- 2017-04-06 IL IL299204A patent/IL299204A/en unknown
- 2017-04-06 PT PT177183043T patent/PT3439661T/pt unknown
- 2017-04-06 ES ES17718304T patent/ES2893126T3/es active Active
- 2017-04-06 EP EP21189296.3A patent/EP3970724A1/en active Pending
- 2017-04-06 US US16/091,830 patent/US10709707B2/en active Active
- 2017-04-06 KR KR1020237000103A patent/KR102512777B1/ko active Active
-
2018
- 2018-10-03 IL IL262102A patent/IL262102B/en unknown
- 2018-10-05 PH PH12018502154A patent/PH12018502154A1/en unknown
- 2018-10-05 MX MX2021010399A patent/MX2021010399A/es unknown
- 2018-11-06 ZA ZA2018/07438A patent/ZA201807438B/en unknown
-
2020
- 2020-04-17 US US16/852,225 patent/US20200345734A1/en not_active Abandoned
-
2022
- 2022-01-24 IL IL290069A patent/IL290069B2/en unknown
- 2022-06-14 JP JP2022095460A patent/JP2022120125A/ja active Pending
-
2024
- 2024-05-29 JP JP2024086805A patent/JP2024103594A/ja active Pending
- 2024-09-05 US US18/825,758 patent/US20250000861A1/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6277855B1 (en) * | 2000-04-21 | 2001-08-21 | Inspire Pharmaceuticals, Inc. | Method of treating dry eye disease with nicotinic acetylcholine receptor agonists |
| WO2004039366A1 (en) * | 2002-11-01 | 2004-05-13 | Pharmacia & Upjohn Company Llc | Nicotinic acetylcholine agonists in the treatment of glaucoma and retinal neuropathy |
| CN102216289A (zh) * | 2008-10-14 | 2011-10-12 | 塞扣吉尼克斯公司 | 烟碱乙酰胆碱受体配体及其用途 |
| WO2010065443A1 (en) * | 2008-12-01 | 2010-06-10 | Targacept, Inc. | Synthesis and novel salt forms of (r)-5-((e)-2-(pyrrolidin-3-ylvinyl)pyrimidine |
| CN109310692B (zh) * | 2016-04-07 | 2022-01-25 | 奥伊斯特普安生物制药公司 | 治疗眼部病状的方法 |
Non-Patent Citations (1)
| Title |
|---|
| Efficacy and Safety of Single-dose OC-02 (Simpinicline Solution) Nasal Spray on Signs and Symptoms of Dry Eye Disease: The PEARL Phase II Randomized Trial;Gail L. Torkildsen, et al.;《Clinical Therapeutics》;第44卷(第9期);第1178-1186页 * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN114533737B (zh) | 治疗眼部病状的方法 | |
| CN107106542B (zh) | 治疗眼部病状的方法 | |
| HK40063370A (en) | Methods of treating ocular conditions | |
| HK40004067B (en) | Methods of treating ocular conditions | |
| BR112018070497B1 (pt) | Métodos e formulações farmacêuticas para tratamento de condições oculares | |
| CA3020170C (en) | Methods of treating ocular conditions | |
| EA047371B1 (ru) | Применение соединения при лечении сухости глаз или дискомфорта в глазах | |
| EA040442B1 (ru) | Применение соединения при лечении сухости глаз или дискомфорта в глазах | |
| HK40035962A (en) | Methods of treating ocular conditions | |
| HK40035961A (en) | Methods of treating ocular conditions | |
| HK40035961B (zh) | 治疗眼部病状的方法 | |
| HK40035962B (zh) | 治疗眼部病状的方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |